Experimental approaches to the study of HIV-1 latency

[1]  J. Karn,et al.  Recruitment of TFIIH to the HIV LTR is a rate‐limiting step in the emergence of HIV from latency , 2006, The EMBO journal.

[2]  R. Arora,et al.  Integration of Human Immunodeficiency Virus Type 1 in Untreated Infection Occurs Preferentially within Genes , 2006, Journal of Virology.

[3]  A. MacNeil,et al.  Genomic Sites of Human Immunodeficiency Virus Type 2 (HIV-2) Integration: Similarities to HIV-1 In Vitro and Possible Differences In Vivo , 2006, Journal of Virology.

[4]  Eric Verdin,et al.  The SWI/SNF Chromatin-remodeling Complex Is a Cofactor for Tat Transactivation of the HIV Promoter* , 2006, Journal of Biological Chemistry.

[5]  Claus O. Wilke,et al.  Residual Human Immunodeficiency Virus Type 1 Viremia in Some Patients on Antiretroviral Therapy Is Dominated by a Small Number of Invariant Clones Rarely Found in Circulating CD4+ T Cells , 2006, Journal of Virology.

[6]  R. Siliciano,et al.  Nuclear Retention of Multiply Spliced HIV-1 RNA in Resting CD4+ T Cells , 2006, PLoS pathogens.

[7]  A. Abbas,et al.  Control of CD4+ T‐cell memory by cytokines and costimulators , 2006, Immunological reviews.

[8]  E. Verdin,et al.  NF‐κB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation , 2006, The EMBO journal.

[9]  T. Naito,et al.  Analysis of Human Immunodeficiency Virus Type 1 Integration by Using A Specific, Sensitive and Quantitative Assay Based on Real-time Polymerase Chain Reaction , 2006, Virus Genes.

[10]  Cheryl Jennings,et al.  Depletion of latent HIV-1 infection in vivo: a proof-of-concept study , 2005, The Lancet.

[11]  Jared E. Toettcher,et al.  Stochastic Gene Expression in a Lentiviral Positive-Feedback Loop: HIV-1 Tat Fluctuations Drive Phenotypic Diversity , 2005, Cell.

[12]  N. Pedersen,et al.  Suppression of Virus Load by Highly Active Antiretroviral Therapy in Rhesus Macaques Infected with a Recombinant Simian Immunodeficiency Virus Containing Reverse Transcriptase from Human Immunodeficiency Virus Type 1 , 2005, Journal of Virology.

[13]  Mary K. Lewinski,et al.  Genome-Wide Analysis of Chromosomal Features Repressing Human Immunodeficiency Virus Transcription , 2005, Journal of Virology.

[14]  W. Greene,et al.  Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells , 2005, Nature.

[15]  Matthew C Strain,et al.  Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. , 2005, The Journal of infectious diseases.

[16]  Qingsheng Li,et al.  Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells , 2005, Nature.

[17]  Thomas C. Quinn,et al.  A Novel Assay Allows Genotyping of the Latent Reservoir for Human Immunodeficiency Virus Type 1 in the Resting CD4+ T Cells of Viremic Patients , 2005, Journal of Virology.

[18]  Tara L. Kieffer,et al.  Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. , 2005, JAMA.

[19]  Yan Zhou,et al.  T Cells + Cd4 Type 1 Decay following Entry into Resting Kinetics of Human Immunodeficiency Virus , 2004 .

[20]  Tara L. Kieffer,et al.  G→A Hypermutation in Protease and Reverse Transcriptase Regions of Human Immunodeficiency Virus Type 1 Residing in Resting CD4+ T Cells In Vivo , 2005, Journal of Virology.

[21]  O. Delelis,et al.  Alu-LTR real-time nested PCR assay for quantifying integrated HIV-1 DNA. , 2005, Methods in molecular biology.

[22]  R. Siliciano,et al.  The multifactorial nature of HIV-1 latency. , 2004, Trends in molecular medicine.

[23]  N. Pedersen,et al.  Efavirenz Therapy in Rhesus Macaques Infected with a Chimera of Simian Immunodeficiency Virus Containing Reverse Transcriptase from Human Immunodeficiency Virus Type 1 , 2004, Antimicrobial Agents and Chemotherapy.

[24]  Robert F. Siliciano,et al.  Analysis of Human Immunodeficiency Virus Type 1 Transcriptional Elongation in Resting CD4+ T Cells In Vivo , 2004, Journal of Virology.

[25]  S. Zeichner,et al.  Host Cell Gene Expression during Human Immunodeficiency Virus Type 1 Latency and Reactivation and Effects of Targeting Genes That Are Differentially Expressed in Viral Latency , 2004, Journal of Virology.

[26]  D. Hazuda,et al.  Integrase Inhibitors and Cellular Immunity Suppress Retroviral Replication in Rhesus Macaques , 2004, Science.

[27]  R. Siliciano,et al.  Resting CD4+ T Cells from Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Individuals Carry Integrated HIV-1 Genomes within Actively Transcribed Host Genes , 2004, Journal of Virology.

[28]  Yassine Taoufik,et al.  The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution , 2004, AIDS.

[29]  C. Verhofstede,et al.  Drug-Resistant Variants That Evolve During Nonsuppressive Therapy Persist in HIV-1–Infected Peripheral Blood Mononuclear Cells After Long-Term Highly Active Antiretroviral Therapy , 2004, Journal of acquired immune deficiency syndromes.

[30]  Tara L. Kieffer,et al.  Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. , 2004, The Journal of infectious diseases.

[31]  Mario Roederer,et al.  T-Cell Subsets That Harbor Human Immunodeficiency Virus (HIV) In Vivo: Implications for HIV Pathogenesis , 2004, Journal of Virology.

[32]  Thomas C. Quinn,et al.  Continued Production of Drug-Sensitive Human Immunodeficiency Virus Type 1 in Children on Combination Antiretroviral Therapy Who Have Undetectable Viral Loads , 2004, Journal of Virology.

[33]  C. Wijmenga,et al.  The gene product Murr1 restricts HIV-1 replication in resting CD4+ lymphocytes , 2003, Nature.

[34]  J. Zack,et al.  Identification of T cell-signaling pathways that stimulate latent HIV in primary cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Mario Clerici,et al.  Productive Infection Maintains a Dynamic Steady State of Residual Viremia in Human Immunodeficiency Virus Type 1-Infected Persons Treated with Suppressive Antiretroviral Therapy for Five Years , 2003, Journal of Virology.

[36]  John W. Mellors,et al.  New Real-Time Reverse Transcriptase-Initiated PCR Assay with Single-Copy Sensitivity for Human Immunodeficiency Virus Type 1 RNA in Plasma , 2003, Journal of Clinical Microbiology.

[37]  D. Hamer,et al.  Molecular characterization, reactivation, and depletion of latent HIV. , 2003, Immunity.

[38]  B. Peterlin,et al.  Transcriptional Profiles of Latent Human Immunodeficiency Virus in Infected Individuals: Effects of Tat on the Host and Reservoir , 2003, Journal of Virology.

[39]  R. Siliciano,et al.  Analysis of Human Immunodeficiency Virus Type 1 Gene Expression in Latently Infected Resting CD4+ T Lymphocytes In Vivo , 2003, Journal of Virology.

[40]  Shawn M. Burgess,et al.  Transcription Start Regions in the Human Genome Are Favored Targets for MLV Integration , 2003, Science.

[41]  R. Siliciano,et al.  Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells , 2003, Nature Medicine.

[42]  E. Verdin,et al.  HIV reproducibly establishes a latent infection after acute infection of T cells in vitro , 2003, The EMBO journal.

[43]  R. Siliciano,et al.  Resting CD4+ T Lymphocytes but Not Thymocytes Provide a Latent Viral Reservoir in a Simian Immunodeficiency Virus-Macaca nemestrina Model of Human Immunodeficiency Virus Type 1-Infected Patients on Highly Active Antiretroviral Therapy , 2003, Journal of Virology.

[44]  D. Richman,et al.  Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: Intrinsic stability predicts lifelong persistence , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[45]  R. Lempicki,et al.  Gene expression and viral prodution in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[46]  J. Sprent,et al.  T cell memory. , 2003, Annual review of immunology.

[47]  Y. Korin,et al.  Interleukin-7 Induces Expression of Latent Human Immunodeficiency Virus Type 1 with Minimal Effects on T-Cell Phenotype , 2002, Journal of Virology.

[48]  Giuseppe Nunnari,et al.  Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy. , 2002, The Journal of infectious diseases.

[49]  M. Malim,et al.  A Sensitive, Quantitative Assay for Human Immunodeficiency Virus Type 1 Integration , 2002, Journal of Virology.

[50]  Thomas C. Quinn,et al.  Persistence of Wild-Type Virus and Lack of Temporal Structure in the Latent Reservoir for Human Immunodeficiency Virus Type 1 in Pediatric Patients with Extensive Antiretroviral Exposure , 2002, Journal of Virology.

[51]  Yan Zhou,et al.  Molecular Characterization of Preintegration Latency in Human Immunodeficiency Virus Type 1 Infection , 2002, Journal of Virology.

[52]  Paul Shinn,et al.  HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots , 2002, Cell.

[53]  Y. Korin,et al.  Effects of Prostratin on T-Cell Activation and Human Immunodeficiency Virus Latency , 2002, Journal of Virology.

[54]  M. Boyd,et al.  Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. , 2001, Blood.

[55]  R. Siliciano,et al.  HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy. , 2001, JAMA.

[56]  Frederic D. Bushman,et al.  A quantitative assay for HIV DNA integration in vivo , 2001, Nature Medicine.

[57]  A. Jordan,et al.  The site of HIV‐1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation , 2001, The EMBO journal.

[58]  Christina M. R. Kitchen,et al.  Generation of HIV latency during thymopoiesis , 2001, Nature Medicine.

[59]  R Hoh,et al.  Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. , 2001, The New England journal of medicine.

[60]  A. Khoruts,et al.  In vivo activation of antigen-specific CD4 T cells. , 2001, Annual review of immunology.

[61]  R. Shafer,et al.  A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies. , 2001, HIV sequence compendium.

[62]  R. Siliciano,et al.  Biphasic decay of latently infected CD4+ T cells in acute human immunodeficiency virus type 1 infection. , 2000, The Journal of infectious diseases.

[63]  Robert F. Siliciano,et al.  Characterization of Chemokine Receptor Utilization of Viruses in the Latent Reservoir for Human Immunodeficiency Virus Type 1 , 2000, Journal of Virology.

[64]  R. Siliciano,et al.  A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children. , 2000, The Journal of clinical investigation.

[65]  Christos J. Petropoulos,et al.  A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1 , 2000, Antimicrobial Agents and Chemotherapy.

[66]  Battaglia,et al.  Electrospray ionization mass spectrometry of synthetic oligonucleotides using 2-propanol and spermidine , 2000, Rapid communications in mass spectrometry : RCM.

[67]  T V Perneger,et al.  Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia , 2000, AIDS.

[68]  J. J. Henning,et al.  Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.

[69]  Alan S. Perelson,et al.  The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy , 2000, Nature Medicine.

[70]  D. Richman,et al.  Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. , 1999, Science.

[71]  J Witek,et al.  Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. , 1999, JAMA.

[72]  Y. Korin,et al.  Nonproductive Human Immunodeficiency Virus Type 1 Infection in Nucleoside-Treated G0 Lymphocytes , 1999, Journal of Virology.

[73]  M. Dybul,et al.  Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy , 1999, Nature Medicine.

[74]  A. Perelson,et al.  Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. , 1999, The New England journal of medicine.

[75]  J. Lisziewicz,et al.  Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy , 1999, Nature Medicine.

[76]  A. Rice,et al.  Tat-Associated Kinase, TAK, Activity Is Regulated by Distinct Mechanisms in Peripheral Blood Lymphocytes and Promonocytic Cell Lines , 1998, Journal of Virology.

[77]  H. Vahaboğlu,et al.  Activities of cefepime and five other antibiotics against nosocomial PER-1-type and/or OXA-10-type beta-lactamase-producing Pseudomonas aeruginosa and Acinetobacter spp. , 1998, The Journal of antimicrobial chemotherapy.

[78]  T. Chun,et al.  Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[79]  Brendan Larder,et al.  A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs , 1998, Antimicrobial Agents and Chemotherapy.

[80]  C. Van Lint,et al.  Mutations in the tat Gene Are Responsible for Human Immunodeficiency Virus Type 1 Postintegration Latency in the U1 Cell Line , 1998, Journal of Virology.

[81]  M A Nowak,et al.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[82]  D. Richman,et al.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. , 1997, Science.

[83]  R Brookmeyer,et al.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.

[84]  Kim Bottomly,et al.  Differential T cell receptor‐mediated signaling in naive and memory CD4 T cells , 1997, European journal of immunology.

[85]  Alan S. Perelson,et al.  Decay characteristics of HIV-1-infected compartments during combination therapy , 1997, Nature.

[86]  R. Siliciano,et al.  Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection , 1997, Nature.

[87]  G. Nolan,et al.  The T cell activation factor NF-ATc positively regulates HIV-1 replication and gene expression in T cells. , 1997, Immunity.

[88]  L. P. Zhao,et al.  HIV Quasispecies and Resampling , 1996, Science.

[89]  C. Van Lint,et al.  A point mutation in the HIV-1 Tat responsive element is associated with postintegration latency. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[90]  Robert F. Siliciano,et al.  In vivo fate of HIV-1-infected T cells: Quantitative analysis of the transition to stable latency , 1995, Nature Medicine.

[91]  D. Richman,et al.  Establishment of a stable, inducible form of human immunodeficiency virus type 1 DNA in quiescent CD4 lymphocytes in vitro , 1995, Journal of virology.

[92]  Martin A. Nowak,et al.  Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.

[93]  A. Perelson,et al.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.

[94]  J. Margolick,et al.  CD8+ lymphocyte activation at human immunodeficiency virus type 1 seroconversion: development of HLA-DR+ CD38- CD8+ cells is associated with subsequent stable CD4+ cell levels. The Multicenter AIDS Cohort Study Group. , 1994, The Journal of infectious diseases.

[95]  A. Rabson,et al.  NF-κ B-Dependent and -Independent Pathways of HIV Activation in a Chronically Infected T Cell Line , 1994 .

[96]  M. Groudine,et al.  Cellular latency in human immunodeficiency virus-infected individuals with high CD4 levels can be detected by the presence of promoter-proximal transcripts. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[97]  S. J. Clark,et al.  High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. , 1993, Science.

[98]  O. Bagasra,et al.  Blocked early-stage latency in the peripheral blood cells of certain individuals infected with human immunodeficiency virus type 1. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[99]  M. Bukrinsky,et al.  Active nuclear import of human immunodeficiency virus type 1 preintegration complexes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[100]  J. Zack,et al.  Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle , 1992, Journal of virology.

[101]  M P Dempsey,et al.  Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. , 1991, Science.

[102]  J. McCune,et al.  Human T cells in the SCID-hu mouse are phenotypically normal and functionally competent. , 1991, Journal of immunology.

[103]  M. Malim,et al.  HIV-1 structural gene expression requires the binding of multiple Rev monomers to the viral RRE: Implications for HIV-1 latency , 1991, Cell.

[104]  D. Baltimore,et al.  Cells nonproductively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: A molecular model for latency , 1990, Cell.

[105]  Jerome A. Zack,et al.  HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure , 1990, Cell.

[106]  A. Fauci,et al.  Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[107]  J. Justement,et al.  Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[108]  I. Weissman,et al.  The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. , 1988, Science.

[109]  B. Franza,et al.  The same inducible nuclear proteins regulates mitogen activation of both the interleukin-2 receptor-alpha gene and type 1 HIV , 1988, Cell.

[110]  A. Cann,et al.  HIV-1 production from infected peripheral blood T cells after HTLV-I induced mitogenic stimulation. , 1988, Science.

[111]  P. Luciw,et al.  Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product , 1987, Nature.

[112]  J. Justement,et al.  Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. , 1987, Science.

[113]  P. Luciw,et al.  Human immunodeficiency virus long terminal repeat responds to T-cell activation signals. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[114]  G. Nabel,et al.  An inducible transcription factor activates expression of human immunodeficiency virus in T cells , 1987, Nature.

[115]  J. Margolick,et al.  Amplification of HTLV-III/LAV infection by antigen-induced activation of T cells and direct suppression by virus of lymphocyte blastogenic responses. , 1987, Journal of immunology.

[116]  J. Justement,et al.  Tumor necrosis factor a induces expression of human immunodeficiency virus in a chronically infected T-cell clone , 2022 .